Your session is about to expire
← Back to Search
Treatment for Frontotemporal Dementia
N/A
Recruiting
Led By Bradley Boeve, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 year, 2 year, 3 year, 4 year, 5 year
Awards & highlights
Summary
This trial is for a research consortium studying frontotemporal lobar degeneration (FTLD), a type of dementia. The study will last for 2019 and beyond.
Eligible Conditions
- Gene Mutation
- Frontotemporal Dementia
- TBK1 Gene
- Progressive Supranuclear Palsy
- Frontotemporal Lobar Degeneration
- Corticobasal Degeneration
- Primary Progressive Aphasia
- Amyotrophic Lateral Sclerosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 1 year, 2 year, 3 year, 4 year, 5 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 year, 2 year, 3 year, 4 year, 5 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Brain Volumes
Change in Multidomain Impairment Rating (MIR) Scale
Change in NIH Examiner Executive Composite Score
Secondary outcome measures
Plasma Neurofilament Light Chain Analysis
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,298 Previous Clinical Trials
3,956,345 Total Patients Enrolled
12 Trials studying Frontotemporal Dementia
10,150 Patients Enrolled for Frontotemporal Dementia
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,362 Previous Clinical Trials
648,650 Total Patients Enrolled
13 Trials studying Frontotemporal Dementia
5,178 Patients Enrolled for Frontotemporal Dementia
University of California, San FranciscoOTHER
2,551 Previous Clinical Trials
15,255,786 Total Patients Enrolled
15 Trials studying Frontotemporal Dementia
6,116 Patients Enrolled for Frontotemporal Dementia
Share this study with friends
Copy Link
Messenger